Dumfries & Galloway Health Board
Prescribing Support Team

Formulary

NHS Dumfries & Galloway formulary offers guidance on the first and second choice drugs across the complete range of therapeutic areas. Prescribing by following guidance in a formulary is one of the many strategies designed to maximise health gain from our prescribing budget. Its place is to promote evidence-based cost effective prescribing across primary and secondary care. Access to the Word document is available by clicking on the download option below. This lists all drugs under BNF codes.

The electronic formulary, which is installed into all EMISS practices, is disease specific. For example if the diagnosis was Impetigo by typing in .IM in the top section of the drug formulary screen, the first choice complete with doses would populate the fields.

Before any drug is placed in the formulary we will have reached an agreement with secondary care that they stock the formulary choice to ensure continuity of medicines.

The D & G joint formulary does not of course take away prescriber’s rights to determine what is clinically most appropriate for their patients, nor their responsibility for that decision. There will always be additions and deletions to be made; improvements to the electronic format; audits of compliance to be carried out and public access to be enabled if the Formulary is to remain a ‘live’ and relevant document.

NHS D & G Joint Formulary 2021 Version 2 Update

This is the fourteenth version of the formulary (due to the pandemic 2020 was not published on line or paper). This formulary will be updated as changes are made through the formulary group which is a sub group of the ADTC committee.

24 Aug 21

Primary Care Anitbiotics and Kidney Handbook Document

Primary Care Anitbiotics and Kidney Handbook Document

4 Sep 20

NHS D&G Pharmaceutical Industry Sponsorship contract

NHS Dumfries and Galloway policy states that when a pharmaceutical company wishes to sponsor an event held in NHS property or under the auspices of NHS Dumfries and Galloway, advertising of the sponsoring company’s products is restricted to those products listed in the joint formulary.

14 Apr 09